Ipragliflozin

Drug Profile

Ipragliflozin

Alternative Names: ASP-1941; Ipragliflozin L-Proline; Suglat

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astellas Pharma; Kotobuki Pharmaceutical
  • Developer Astellas Pharma; MSD KK; Seoul National University Hospital
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 25 Apr 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in South Korea (PO) (NCT03076112)
  • 01 Mar 2017 Merck completes a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (PO) (NCT02564211)
  • 04 Feb 2017 Astellas Pharma completes a phase I trial in Type-2 diabetes mellitus in Japan (UMIN000019071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top